Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has soared by 2.61 in relation to previous closing price of 1.53. Nevertheless, the company has seen a gain of 4.67% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-27 that Taysha Gene Therapies’ TSHA-102 tackles Rett syndrome’s root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA’s main value driver, and it appears safe and effective in both of its trial’s high and low-dose cohorts. TSHA-102 has an RMAT designation, which could accelerate its approval process. Management anticipates a regulatory submission by 2H2025.
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
TSHA has 36-month beta value of 0.90. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 153.61M, and currently, short sellers hold a 15.59% ratio of that float. The average trading volume of TSHA on February 05, 2025 was 4.54M shares.
TSHA’s Market Performance
TSHA’s stock has seen a 4.67% increase for the week, with a -15.14% drop in the past month and a -7.10% fall in the past quarter. The volatility ratio for the week is 7.42%, and the volatility levels for the past 30 days are at 7.80% for Taysha Gene Therapies Inc. The simple moving average for the past 20 days is -3.00% for TSHA’s stock, with a -31.20% simple moving average for the past 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at -21.51% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.66% of loss for the given period.
Volatility was left at 7.80%, however, over the last 30 days, the volatility rate increased by 7.42%, as shares sank -18.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.94% lower at present.
During the last 5 trading sessions, TSHA rose by +4.67%, which changed the moving average for the period of 200-days by -35.92% in comparison to the 20-day moving average, which settled at $1.6185. In addition, Taysha Gene Therapies Inc saw -9.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 1,333,333 shares at the price of $2.25 back on Jun 27 ’24. After this action, Manning Paul B now owns 1,333,333 shares of Taysha Gene Therapies Inc, valued at $2,999,999 using the latest closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -8.81 for the present operating margin
- 0.9 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -2.3. The total capital return value is set at -0.58. Equity return is now at value -114.77, with -12.11 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -1.26. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -110.12.
Currently, EBITDA for the company is -105.2 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 22.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.51.
Conclusion
To put it simply, Taysha Gene Therapies Inc (TSHA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
